Clinical Trial Considerations in Cerebral Protection for TAVR Patients

An examination of study design, considerations and endpoints

Transcatheter aortic valve replacement (TAVR) changed the treatment of high-risk patients with severe aortic stenosis, while also raising concerns of complications, such as increased risk for stroke. The entry of embolic protection devices (EPD) that deflect or collect potentially damaging micro-debris associated with TAVR, presents an evolving risk-reduction safety strategy for patients. This paper explores the potential for cerebral protection devices and factors we believe sponsors should consider when developing or using EPDs in clinical trials.

Cerebral ProtectionLearning Objectives:

  • Understand the latest research and clinical outcomes of ongoing EPD studies
  •  Recognize appropriate use of DW-MRI and what parameters to assess
  • Learn how to select measureable endpoints to address efficacy and safety
  • Review critical trial design considerations, including site selection, training, patient enrollment and pre-screening

By submitting this form you agree to our Terms of Use and Privacy Policy. Information provided by you may be collected and automatically stored in our database and may be used for sending you additional information about Novella and our services. Such information also may be transferred to Novella companies in other countries.
Copyright © 2018 Novella Clinical and its affiliates. All rights reserved.